Harrill1: Drug study: Clinico-pathological survey of the liver and adverse reactions in response to isoniazid treatment in females of 34 inbred strains of mice (2011)

Church RJ, Wu H, Mosedale M, Sumner SJ, Pathmasiri W, Kurtz CL, Pletcher MT, Eaddy JS, Pandher K, Singer M, Batheja A, Watkins PB(7), Adkins K, Harrill AH(8). A systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis. Toxicol Sci. 2014 Aug 1;140(2):481-92. doi: 10.1093/toxsci/kfu094. Epub 2014 May 20.   PubMed 24848797     FullText


       
Harrill1 downloads
• Download Harrill1 project data set     one row per animal, one column per trait
• Download Harrill1 strain means, SD, N, etc.     one row per strain/sex/measure
• Harrill1 supplementary data
Participants Alison Harrill       University of Arkansas for Medical Sciences Little Rock, AR
ContactAlison Harrill     AHHarrill@uams.edu     Lab web site
AcknowledgementsFunding provided by Pfizer, Inc., AstraZeneca, and Lilly; International Life Sciences Institute Health and Environmental Sciences Institute (ILSI HESI)
Project type Phenotype strain survey data set
MPD identifiersHarrill1     MPD:395
Data changelog No updates/corrections.       Initial release date: 06/2014.
Formatted citation
Click above to copy-paste the entire citation for this MPD web page.
A treatment/control study of isoniazid. Treated group received Rx daily for 3 days. Control group received vehicle only for 3 days. See protocol timeline for details. All measurements taken on day 4 unless otherwise stated.

Summary of procedures that were conducted
• body weight Body weight. Isoniazid-treated vs. control.
• organ weights Body, liver, kidney weights. Isoniazid-treated vs. control.
• metabolic panel Alanine transaminase. Isoniazid-treated vs. control.
• lipid profile Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control.
• histopathology Liver pathology scores. Isoniazid-treated vs. control.
Mice: inbred   34 strains   ♀   age 8-10wks   2 cohorts

Select table page: First Prev Next Last
Data set MPD ID Procedure / Protocol Drug or Challenge Phenotype Measure Panel No. of Strains Sex Age Sample Size (Avg)
    Harrill1 39501 body weight (none) body weight day 1   [g]     control group    treatment group inbred 34 f 8-10wks N=4
    Harrill1 39503 body weight isoniazid body weight day 4   [g]     control    isoniazid inbred 33 f 8-10wks N=4
    Harrill1 39505 organ weights isoniazid liver weight   [g]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39507 organ weights isoniazid liver weight as percent of body weight   [%]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39511 organ weights isoniazid spleen weight   [g]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39513 organ weights isoniazid spleen weight as percent of body weight   [%]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39521 metabolic panel isoniazid alanine transaminase (serum ALT)   [IU/L]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39526 lipid profile isoniazid hepatic cholesterol (CHOL)   [mg/dL]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39531 lipid profile isoniazid hepatic triglycerides (TG)   [mg/dL]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39541 histopathology isoniazid lymphohistiocytic, portal, multifocal infiltrate   [score]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39546 histopathology isoniazid hepatocytic cytoplasmic, microvesiculation, multifocal   [score]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39551 histopathology isoniazid hepatocytic cytoplasmic, microvesiculation, diffuse   [score]     control    isoniazid inbred 34 f 8-10wks N=4
    Harrill1 39556 histopathology isoniazid hepatocytic hypertrophy, panlobular, diffuse   [score]     control    isoniazid inbred 34 f 8-10wks N=4
    All boxes             To see more rows use the paging control at top.